Effect of NIC 002-induced antibodies on the pharmacokinetics of nicotine during cigarette smoking.

Trial Profile

Effect of NIC 002-induced antibodies on the pharmacokinetics of nicotine during cigarette smoking.

Suspended
Phase of Trial: Phase II

Latest Information Update: 18 Aug 2011

At a glance

  • Drugs NIC 002 (Primary)
  • Indications Smoking withdrawal; Substance-related disorders
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Cytos Biotechnology
  • Most Recent Events

    • 18 Aug 2011 Status changed from not yet recruiting to suspended.
    • 05 Nov 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top